VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISA 2022 | Current and emerging antibody-based immunotherapies in AL amyloidosis

Maximilian Steinhardt, MD, University Hospital Würzburg, Würzburg, Germany, comments on the efficacy of currently available and emerging antibodies in the treatment of AL amyloidosis, including daratumumab, elotuzumab, and antibodies targeting amyloid deposits. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter